Protalix BioTherapeutics (PLX) Non-Current Deffered Revenue (2010 - 2022)

Protalix BioTherapeutics' Non-Current Deffered Revenue history runs 13 years deep, the most recent figure standing at $5.9 million for Q2 2022.

• In Q2 2022, Non-Current Deffered Revenue rose 364.54% year-over-year to $5.9 million; the TTM figure through Jun 2022 stood at $5.9 million (up 364.54% YoY), while the FY2021 annual figure was $11.8 million, up 587.06% from the prior year.
• Non-Current Deffered Revenue was $5.9 million for Q2 2022 at Protalix BioTherapeutics, roughly flat from $5.9 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $34.9 million in Q2 2019 to a low of $858000.0 in Q1 2021.
• Historically, Non-Current Deffered Revenue has averaged $15.0 million across 5 years, with a median of $9.5 million in 2020.
• The sharpest annual moves came in 2020 and 2021: Non-Current Deffered Revenue sank 94.64% in 2020, then surged 587.06% in 2021.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $33.0 million in 2018, then sank by 48.59% to $17.0 million in 2019, then slumped by 89.89% to $1.7 million in 2020, then soared by 587.06% to $11.8 million in 2021, then tumbled by 50.0% to $5.9 million in 2022.
• The last three Non-Current Deffered Revenue figures came in at $5.9 million (Q2 2022), $5.9 million (Q1 2022), and $11.8 million (Q4 2021), per Business Quant data.